In patients with non-FH and mixed hyperlipidemia, the REMAIN-2 Trial demonstrates the long-term safety and effectiveness of recaticimab.

Published Date: 01 Dec 2023

China: A recent study has shown the long-term efficacy and safety of add-on recaticimab as a treatment option in patients with non-familial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot